microdosing tirzepatide for hashimoto's FITISH GLP-1 PROGRAM Microdosing GLP-1's for Weight Loss

Patent protections for semaglutide (Ozempic/Wegovy) expire in 2026 in Canada, India, Brazil and China, opening the door for lower-cost biosimilar generic versions

Furthermore, while their customer service is excellent, they are strictly "Research Only." If a customer emails them asking for medical advice or dosing protocols for human use, they willrightfullyterminate the conversation and potentially ban the account

[PMID:21541336] [22]Garca-Rodrguez JL, et al

The allodynia associated with semaglutide appears to resolve with dose reduction or discontinuation, indicating functional change rather than structural damage